CURRICULUM VITAE
OREGON HEALTH SCIENCES UNIVERSITY
NAME
Kristin Knight
DATE 12/10/2013
PRESENT POSITION AND ADDRESS
Academic Rank:
Associate Professor of Pediatrics
Department/
Division:
Department of Pediatrics, Institute on Development and Disability
School of Medicine
Professional Address:
CDRC 707 SW Gaines
Portland OR 97239
E-Mail Address:
[email protected]
II. EDUCATION
Undergraduate and Graduate (Include Year, Degree, and Institution):
1993, Portland State University, Bachelor of Science, Speech and Hearing Science
1995, Portland State University, Master of Science, Speech and Hearing Science
Terminal degree in the field at that time.
Certification (Include Board, Number, Date, and Recertification):
Certificate of Clinical Competence in Audiology (CCC-A), American Speech-Language Hearing Association (ASHA) #09128998, 1995 - present. Recertification date: 12/31/2013
Licenses (Include State, Date, Status, Number, and Renewal Date):
State of Oregon Audiology License, Board of Examiners in Speech Pathology and Audiology, #22035, 1999 - present. Renewal date 1/30/2014
III. PROFESSIONAL EXPERIENCE
Academic (Include Year, Position, and Institution):
2011- Present Audiology Training Coordinator, Leadership on Neurodevelopmental and Related Disabilities (LEND), Institute on Development and Disability, Portland, Oregon
2007 - 2014 Assistant Professor, Pediatric Audiology, Department of Pediatrics, Institute on Development and Disability, Child Development and Rehabilitation Center and Doernbecher Children's Hospital, Oregon Health and Science University, Portland Oregon.
1999- 2007 Instructor, Pediatric Audiology, Department of Pediatrics, Institute on Development and Disability, Child Development and Rehabilitation Center and Doernbecher Children's Hospital, Oregon Health and Science University, Portland Oregon.
2002 - Present Adjunct Instructor, Department of Speech and Hearing Science, Portland State University, Portland, Oregon
Administrative (Include Year, Position, and Institution):
2006 - 2017 Discipline Director, Pediatric Audiology, Department of Pediatrics, Institute on Development and Disability, Child Development and Rehabilitation Center and Doernbecher Children's Hospital, Oregon Health and Science University, Portland, Oregon
2003 -2006 Administrative Coordinator, Pediatric Audiology, Department of Pediatrics, Institute on Development and Disability, Oregon Health and Science University, Portland, Oregon
Other (Include Year, Position, and Institution):
1996 - 1999 Educational Audiologist, Vancouver School District #37, Vancouver, WA.
1998 Clinical Audiologist, Otolaryngology Outpatient Clinic, Oregon Health and Science
University, Portland, Oregon
1995- 1996 Audiology Clinical Fellowship, Leadership on Neurodevelopmental and Related Disabilities, Child Development and Rehabilitation Center, Oregon Health and Science University, Portland, OR.
IV. Honors and Awards
2007 Leadership Education in Neurodevelopmental and Related Disabilities Distinguished Alumna Award
V. SCHOLARSHIP
Area(s) of Research/Scholarly Interest:
Assessment, treatment, and prevention of ototoxicity in children receiving chemotherapy
Diagnosis and management of auditory neuropathy spectrum
Grants and Contracts:
Title: Two-Compartment Models to Improve Brain Tumor Therapy
NIH #5 R01 CA137488-21
PI: Edward Neuwelt, M.D.
NIH-NCI funding: $ 477,492
Dates: 3/2016 – 2/2021
Study audiologist and consultant, .2 FTE
Oregon Leadership Education in Neurodevelopmental Disabilities (LEND) Project
5 T73 MC00034 22-00 HRSA
PI: Amy Costanza Smith, PhD
7/01/2011 - 6/30/2022
Role: Audiology training coordinator .15 FTE
Pediatric audiology competitive supplement to Leadership Education in Neurodevelopmental and Related Disabilities (LEND).
PI: Kurt Freeman, PhD
7/2016-7/2021
Publications/Creative Work:
Peer-reviewed
Freyer DR, Brock P, Chang K, Dupuis LL, Epelman S, Knight K, Mills D, Phillips R, Potter E, Risby D, Simpkin P, Sullivan M, Cabral S, Robinson PD, Sung L. Guideline for the Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer. The Lancet Child and Adolescent Health, 2019, doi: https://doi.org/10.1016/S2352-4642(19)30336-0.
Clemens, E; van den Heuvel-Eibrink MM, Mulder RL, Kremer LC, Hudson MM, Skinner R, Constine LS, Bass JK, Kuehni CE, Langer T, van Dalen EC, Bardi E, Bonne NX, Brock PR, Brooks B, Carleton B, Caron E, Chang KW, Johnston K, Knight K, Nathan PC, Orgel E, Prasad PK, Rottenberg J, Scheinemann K, de Vries ACH, Walwyn T, Weiss A, am Zehnhoff-Dinnesen A, Cohn RJ, Landier W. Recommendations for ototoxicity surveillance for survivors of childhood, adolescent, and young adult cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) in collaboration with the PanCare consortium. The Lancet Oncology, 2019:20(1):e29-e41. doi:10.1016/S1470-2045(18)30858-1
Brooks B and Knight K. Ototoxicity monitoring in children treated with platinum chemotherapy. International Journal of Audiology, 2018:57(sup4):S34-S40. doi: 10.1080/14992027.2017.1355570
Konrad-Martin D, Knight KR, McMillan GP, Dreisbach LE, Nelson E, Dille, M. Long term variability of distortion-product otoacoustic emissions in infants and children and its relation to pediatric ototoxicity monitoring. Ear and Hearing, 2017, Dec 26. doi: 10.1097/AUD.0000000000000536
Freyer DR, Chen L, Krailo MD, Knight KR, Bliss B, Pollock BH, Ramdas J, Lange B, Van Hoff D, VanSoelen M; Wiernikowski J, Neuwelt EA; Sung L. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss and survival in children with cancer: results from the children’s oncology group ACCL0431 randomized cohort trial. The Lancet Oncology, 2017, 18(1), 63-74. doi:10.1016/s1470-2045(16)30625-8.
Knight KR, Aplenc R, Bancroft M, Bliss B, Freyer DF, Gillmeister B, Hendreshot H, Kraemer DF, Lindenfeld L, Meza J, Neuwelt E, Pollock BH, Sung L. A group-wide prospective study of ototoxicity assessment in children receiving cisplatin chemotherapy. Journal of Clinical Oncology, 2017, 35(4):440-445. doi: 10.1200/JCO.2016.69.2319
Bass JK, Knight KR, Yock T, Chang KW, Cipkala D, Grewal SS. Evaluation and management of hearing loss following therapy for childhood and adolescent cancers. Pediatric Blood and Cancer, 2016:63(7):1152-62. doi: 10.1002/pbc.25951.
Landier, W, Knight KR, Wong L, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, London WB, Gurney JG, Bhatia S. Ototoxicity in Children with High-Risk Neuroblastoma - Prevalence, Risk Factors, and Concordance of Grading Scales: A Report from the Children's Oncology Group. Journal of Clinical Oncology, January 13, 2014 doi: 10.1200/JCO.2013.51.2038.
Brock P, Knight KR, Freyer D, Campbell KCM Steyger PS, Blakley BW, Rassekh T, Chang KW, Fligor B, Sullivan M, Neuwelt EA. Platinum-induced ototoxicity in children: a consensus review on ototoxicity, otoprotection and monitoring. Journal of Clinical Oncology, 30(19), 2408-17, 2012.
Guillaume DJ, M.D., Knight KR, Kraemer D, Bardo D, Neuwelt EA. Cerebrospinal Fluid Shunting and Hearing Loss in Patients Treated for Medulloblastoma. Journal of Neurosurgery Pediatrics, Apr 9(4): 421-7, 2012
Jahnke K, Kraemer DF, Knight KR, Fortin D, Bell S, Doolittle ND, Muldoon LL, Neuwelt EA. Intrarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal germ cell tumors of the central nervous system. Cancer 112(13):581-588, 2008
Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high frequency audiometry and evoked distortion product otoacoustic emissions in pediatric ototoxicity monitoring. Journal of Clinical Oncology, 25(10): 1190-1195, 2007.
Neuwelt EA, Gilmer Knight K, Lacy C, Nicholson HS, Kraemer DF, Doolittle ND, Hornig G, Muldoon LL. Toxicity Profile of Delayed High Dose Sodium Thiosulfate in Children Treated with Carboplatin in Conjunction with Blood-Brain-Barrier Disruption. Pediatric Blood & Cancer Aug;47(2):174-82, 2006
Gilmer Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in Children Receiving Platinum Chemotherapy: Underestimating a commonly occurring toxicity that may impact academic and social development. Journal of Clinical Oncology 23(34): 8588-8596, 2005.
Chapters
Knight K, Durham H, Carmichael N, Plapinger D. (2008) Audiological assessment of children with autism spectrum disorders in B Buckendorf (Ed) Autism: A Guide for Educators, Clinicians, and Parents. Greenville, South Carolina, Thinking Publications.
Invited Lectures, Conference Presentations or Professorships:
International and National
Knight KR. Monitoring infants and children for ototoxicity. 2019 American Speech-Language Hearing Association Convention, Orlando, FL 11/2019
Knight, KR. Deafness/Hearing Loss and Cochlear Implants in the Pediatric Population. 2019 International Association of Rehabilitation Professionals Annual Conference & 25th Annual International Association of Life Care Planners Symposium, Portland, OR 10/2019.
Knight KR. Ototoxicity of chemotherapeutic agents. 9th Biennial National Center for Rehabilitative Auditory Research Conference: Ototoxicity and Noise Damage: Translating Preclinical Findings to Audiological Management. Portland, OR, 9/2019
Knight KR. Short and Long-term impacts of cisplatin ototoxicity. 25th Annual Blood-Brain-Barrier Consortium Meeting. Portland, OR, 3/2019.
Knight KR. Long-term outcomes and quality of life in childhood cancer survivors treated with cisplatin. Soundwave Symposium. San Diego, CA. 10/2018
Knight KR. Treatment-induced hearing loss in childhood cancer. Externally-Led Patient Focused Drug Development (PFDD) Meeting: Childhood Cancer Hearing Loss. Hyattsville, MD. 9/2018.
Knight KR. Cisplatin ototoxicity: Long term outcomes and quality of life. 24th Annual Blood-Brain-Barrier Consortium Meeting. Portland, OR, 3/2018.
Knight KR. Long term hearing outcomes and socioeconomic impact of cisplatin induced hearing loss. Collaborative Opportunities with the Blood-Brain Barrier Consortium for Diagnostic and Therapeutic Clinical Trials. Society for Neuro-Oncology Annual Meeting, San Francisco, 11/2017.
Knight KR, Long term hearing outcomes and socioeconomic impact of cisplatin ototoxicity. Hearing Loss Impact Symposium at the 49th Congress of the International Society of Pediatric Oncology, Washington DC, 10/2017.
Knight, KR. Hearing outcomes in central nervous system germ cell tumors. 5th International CNS Germ Cell Tumor Symposium. Columbus OH, 6/2017.
Knight KR, Overview and update of the pediatric thiol chemoprotection studies. 23rd Annual Blood-Brain Barrier Consortium Meeting, Skamania WA, 3/2017
Knight KR Treatment-induced ototoxicity in children with standard risk medulloblastoma. Blood-Brain Barrier Mid-Annual Meeting, Portland OR, 10/2016
Knight KR. ACCL05C1: A Group-Wide Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy: A report from the Children’s Oncology Group. Children’s Oncology Group Cancer Control Steering Committee conference call presentation, 5/2016.
Knight, KR. ACCL05C1: A Group-Wide Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy. National Cancer Institute conference call presentation, 1/2016.
Knight KR. Ototoxicity monitoring in children. Invited webinar for Audiology Online, an organization that provides online CEU courses and webinars for international audiologists, hearing instrument specialists, researchers, academics and industry professionals, 11/2015.
Knight KR. ACCL0431 A Randomized Phase III Trial of Sodium Thiosulfate for the Prevention of Cisplatin Ototoxicity in Children. Children’s Oncology Group Fall Meeting, Dallas TX, 10/2015.
.jpg)
